ClinConnect ClinConnect Logo
Search / Trial NCT06841224

The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Feb 18, 2025

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Aged 18-80 years;
  • 2. A confirmed diagnosis of polycystic kidney disease, with a history of peritoneal dialysis catheter placement and regular peritoneal dialysis;
  • 3. Able to tolerate the infusion of more than 1500 mL of dialysis fluid.
  • Exclusion Criteria:
  • 1. Acute complications such as peritonitis or cardiovascular and cerebrovascular events within the past month;
  • 2. History of abdominal surgery or trauma within the past month;
  • 3. History of kidney cyst rupture, infection, or bleeding within the past month;
  • 4. History of abdominal or pelvic organ tumors;
  • 5. History of abdominal pressure-related complications, such as hernias, leaks, or chest-abdominal fistulas;
  • 6. Unable to attend follow-up visits during the study period;
  • 7. Refusal to participate in the study. -

About Peking University First Hospital

Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported